398 related articles for article (PubMed ID: 22804249)
1. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
Chen L; Klein T; Leung PS
Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
[TBL] [Abstract][Full Text] [Related]
2. Combination of Telmisartan and Linagliptin Preserves Pancreatic Islet Cell Function and Morphology in db/db Mice.
Zhao S; Chan LK; Chen L; Cheng TW; Klein T; Leung PS
Pancreas; 2016 Apr; 45(4):584-92. PubMed ID: 26495783
[TBL] [Abstract][Full Text] [Related]
3. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes.
Cheng Q; Law PK; de Gasparo M; Leung PS
J Pharmacol Exp Ther; 2008 Dec; 327(3):683-91. PubMed ID: 18787107
[TBL] [Abstract][Full Text] [Related]
4. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
[TBL] [Abstract][Full Text] [Related]
5. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
8. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
[TBL] [Abstract][Full Text] [Related]
10. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
Ohmura T; Hayashi N; Encinas J
Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
[No Abstract] [Full Text] [Related]
13. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin: in type 2 diabetes mellitus.
Scott LJ
Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
[TBL] [Abstract][Full Text] [Related]
15. Review of linagliptin for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Setter SM
Clin Ther; 2012 May; 34(5):993-1005. PubMed ID: 22440191
[TBL] [Abstract][Full Text] [Related]
16. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Takai S; Sakonjo H; Jin D
J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
20. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
